Cytiva is a global life sciences company focused on advancing and accelerating the development of therapeutics. The company provides innovative technologies, tools, and services that support the discovery, development, and production of biopharmaceuticals, including monoclonal antibodies, mRNA therapies, viral vectors, and cell therapies.
With expertise in bioprocessing, cell therapy, and protein research, Cytiva enables scientists and researchers to bring life-changing treatments to patients faster. Its portfolio includes chromatography systems, filtration solutions, cell culture media, and automation platforms designed to improve efficiency and scalability in drug development and manufacturing.
As part of the Danaher family of science and technology companies, Cytiva combines deep industry knowledge with a commitment to innovation and sustainability. The company serves a global network of pharmaceutical, biotech, and academic institutions, helping them overcome challenges in the path from research to real-world impact.
Cytiva also emphasizes workforce development through training programs and educational resources, empowering teams to stay at the forefront of life sciences innovation. With a presence in over 40 countries, Cytiva is positioned as a key enabler in the future of human health.